129 related articles for article (PubMed ID: 15225090)
1. 3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice.
Taube SE; Gion M; Schilsky RL
Expert Rev Mol Diagn; 2004 Jul; 4(4):431-3. PubMed ID: 15225090
[No Abstract] [Full Text] [Related]
2. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 4.
Eccles SA
IDrugs; 2007 Dec; 10(12):844-7. PubMed ID: 18041676
[No Abstract] [Full Text] [Related]
3. [Individualized anticancer therapies: which regulatory guidelines?].
Bedairia N; Marty M
Bull Cancer; 2008 Oct; 95(10):985-8. PubMed ID: 19004730
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in clinical oncoproteomics.
Jain KK
J BUON; 2007 Sep; 12 Suppl 1():S31-8. PubMed ID: 17935275
[TBL] [Abstract][Full Text] [Related]
5. Biology-driven phase II trials: what is the optimal model for molecular selection?
Andre F; Delaloge S; Soria JC
J Clin Oncol; 2011 Apr; 29(10):1236-8. PubMed ID: 21343554
[No Abstract] [Full Text] [Related]
6. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic biomarkers for molecular cancer therapeutics.
Sarker D; Workman P
Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
[TBL] [Abstract][Full Text] [Related]
8. [Development for and clinical trials of molecular targeting drugs].
Takashima A; Fukuda H; Shibata T
Gan To Kagaku Ryoho; 2010 May; 37(5):822-7. PubMed ID: 20524257
[No Abstract] [Full Text] [Related]
9. Personalized medicine for cancer: from molecular signature to therapeutic choice.
Sikora K
Adv Cancer Res; 2007; 96():345-69. PubMed ID: 17161685
[No Abstract] [Full Text] [Related]
10. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 2.
Searle B; Collins T
IDrugs; 2007 Dec; 10(12):836-9. PubMed ID: 18041674
[No Abstract] [Full Text] [Related]
11. Recent advances in biomarkers for cancer diagnosis and treatment.
Manne U; Srivastava RG; Srivastava S
Drug Discov Today; 2005 Jul; 10(14):965-76. PubMed ID: 16023055
[TBL] [Abstract][Full Text] [Related]
12. Criticism of tumor response criteria raises trial design questions.
Twombly R
J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
[No Abstract] [Full Text] [Related]
13. [Molecular markers having a prognostic or therapeutic value in cancer].
Brousset P
Ann Pathol; 2008 Nov; 28 Spec No 1(1):S69-70. PubMed ID: 18984307
[No Abstract] [Full Text] [Related]
14. Companion diagnostics.
Becker R; Mansfield E
Clin Adv Hematol Oncol; 2010 Jul; 8(7):478-9. PubMed ID: 20864915
[No Abstract] [Full Text] [Related]
15. DualChip microarray as a new tool in cancer research.
Gillet JP; de Longueville F; Remacle J
Expert Rev Mol Diagn; 2006 May; 6(3):295-306. PubMed ID: 16706734
[TBL] [Abstract][Full Text] [Related]
16. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 3.
Collins T
IDrugs; 2007 Dec; 10(12):840-3. PubMed ID: 18041675
[No Abstract] [Full Text] [Related]
17. Biomarkers of clinical trials using molecular inhibitors and radiotherapy: state-of-the-art. Preface.
Bristow RG
Cancer Metastasis Rev; 2008 Sep; 27(3):337-8. PubMed ID: 18427733
[No Abstract] [Full Text] [Related]
18. EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics.
Kibble A
IDrugs; 2007 Jan; 10(1):1-2. PubMed ID: 17187301
[No Abstract] [Full Text] [Related]
19. EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics. Pediatric drugs, biomarkers and new therapies.
Kibble A
IDrugs; 2007 Jan; 10(1):5-7. PubMed ID: 17187303
[No Abstract] [Full Text] [Related]
20. The search for optimal response prediction in cancer leads to a personalized approach.
Van Cutsem E; Ciardiello F
Target Oncol; 2010 Mar; 5(1):3-4. PubMed ID: 20349283
[No Abstract] [Full Text] [Related]
[Next] [New Search]
